Biomarker Cancer ProjectCancer has proven to be a major burden for the Hispanic community, which accounts for nearly 20% of America's population. In fact, the leading cause of death for Hispanic Americans is cancer; one in three Hispanics will be diagnosed with cancer in their lifetime. Despite being at a higher risk for certain cancer types, Hispanic Americans, as compared to their non-Hispanic White counterparts, are underdiagnosed for the most common cancers. Knowing this information, NHMA and Amgen Inc. have partnered to develop a webinar series to educate the public on the impact of cancer on Hispanic Americans and disparities in cancer care and outcomes. View Slides and Recording from Session 1
View Slides and Recording from Session 2View Slides and Recording from Session 3Impact of Cancer among Hispanics InfographicNHMA Biomarker Cancer Project Summary
Past Events: Session 1: Biomarker Testing: Improving Access to Improve Care (NY) | July 14, 2022; 1:00-2:00 PM ET
SlidesBioAgenda
Session 2: Biomarker Testing: Improving Access to Improve Care (IL) | July 21, 2022; 12:00-1:00 PM ETFeaturing a real patient story! SlidesBioAgenda
Session 3: Biomarker Testing: Improving Access to Improve Care (TX) | August 25, 2022; 12:00-1:00 PM ETFeaturing a real patient story!
SlidesBioAgenda
|
